Sedova E S, Shmarov M M, Tutykhina I L, Barykova Iu A, Verkhovskaia L V, Logunov D Iu, Naroditskiĭ B S, Gintsburg A L
Zh Mikrobiol Epidemiol Immunobiol. 2010 May-Jun(3):44-8.
To design and study the properties of candidate vaccines against avian influenza based on recombinant adenoviral vectors expressing H5 hemagglutinin.
Recombinant adenoviral vectors were constructed as described in "Stratagene" (Ad Easy Adenoviral Vector System). For immunization of animals, recombinant candidate vaccines were administered intranasally twice. Titer of hemagglutinating antibodies were measured by hemaglutination inhibition assay.
It was demonstrated that administration of vaccines to animals completely protects them from a lethal dose challenge with H5N2 influenza virus. Protective effect of vaccines remained for 6 months after immunization. Additionally, highly effective cross-protection of the immunized animals against heterologous strain of H5 influenza virus was demonstrated.
Obtained results show good prospects for usage of recombinant adenoviral vectors as a basis for development of new generation effective vaccines against influenza.
设计并研究基于表达H5血凝素的重组腺病毒载体的抗禽流感候选疫苗的特性。
按照“Stratagene”（Ad Easy腺病毒载体系统）所述构建重组腺病毒载体。对动物进行免疫时，重组候选疫苗经鼻内给药两次。通过血凝抑制试验测定血凝抗体滴度。
结果表明，给动物接种疫苗可使其完全免受致死剂量H5N2流感病毒的攻击。免疫后疫苗的保护作用持续6个月。此外，还证明了免疫动物对H5流感病毒异源毒株具有高效的交叉保护作用。
所得结果表明，重组腺病毒载体作为新一代有效抗流感疫苗开发的基础具有良好的应用前景。
